Pages that link to "Q35189103"

The following pages link to Toward a molecular neuropsychiatry of neurodegenerative diseases (Q35189103):

Displaying 29 items.

• PuF, an antimetastatic and developmental signaling protein, interacts with the Alzheimer's amyloid-β precursor protein via a tissue-specific proximal regulatory element (PRE) (Q28706304) (← links)
• Multiprotein Deposits in Neurodegenerative Disorders: Our Experience in the Tissue Brain Bank of Navarra (Q33453702) (← links)
• Neuropsychiatric symptoms in behavioral variant frontotemporal dementia and primary progressive aphasia (Q33943599) (← links)
• Neuroanatomical characteristics of geriatric apathy and depression: a magnetic resonance imaging study (Q35401616) (← links)
• Dementia with lewy bodies: molecular pathogenesis and implications for classification (Q35863395) (← links)
• Behavioural changes and psychological symptoms in dementia disorders (Q36292518) (← links)
• Treatments for behavioural disorders in neurodegenerative diseases: drug development strategies (Q36399561) (← links)
• Recent advances in biomedical applications of accelerator mass spectrometry (Q37266360) (← links)
• Rates of cerebral atrophy differ in different degenerative pathologies (Q37363768) (← links)
• Depression and antidepressants: molecular and cellular aspects. (Q37517285) (← links)
• Early detection of Alzheimer's disease with PET imaging. (Q37701671) (← links)
• Category cued recall following controlled encoding as a neuropsychological tool in the diagnosis of Alzheimer's disease: a review of the evidence (Q37810499) (← links)
• Psychiatric Complications of Dementia (Q37915669) (← links)
• Prefibrillar tau oligomers in mild cognitive impairment and Alzheimer's disease (Q38136863) (← links)
• Evaluation of the new consensus criteria for the diagnosis of primary progressive aphasia using fluorodeoxyglucose positron emission tomography (Q38432227) (← links)
• Pharmacological Therapy for Apathy in Alzheimer's Disease: A Systematic Review and Meta-Analysis (Q38985928) (← links)
• Characterization of a Novel Mutation in SLC1A1 Associated with Schizophrenia (Q42154902) (← links)
• Coexistence of mixed phenotype Creutzfeldt-Jakob disease, Lewy body disease and argyrophilic grain disease plus histological features of possible Alzheimer's disease: a multi-protein disorder in an autopsy case (Q42465019) (← links)
• Association between FDG uptake, CSF biomarkers and cognitive performance in patients with probable Alzheimer's disease (Q46121140) (← links)
• Depressive symptoms and level of physical activity in patients with Alzheimer's disease (Q46258508) (← links)
• The Alzheimer disease-related calcium-binding protein Calmyrin is present in human forebrain with an altered distribution in Alzheimer's as compared to normal ageing brains. (Q46482973) (← links)
• Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: a double-blind, placebo-controlled, randomised clinical trial (Q47958506) (← links)
• Voxel-based morphometry in tau-positive and tau-negative frontotemporal lobar degenerations (Q48447129) (← links)
• Neuropsychiatric disturbances in Parkinson's disease clusters in five groups with different prevalence of dementia. (Q48540399) (← links)
• Metabolic connectomics targeting brain pathology in dementia with Lewy bodies (Q48674580) (← links)
• Clinicopathological features of senile systemic amyloidosis: an ante- and post-mortem study (Q51016842) (← links)
• Clustering Analysis of FDG-PET Imaging in Primary Progressive Aphasia. (Q64891000) (← links)
• Fluctuations in cognitive function in dementia with Lewy bodies (Q79964392) (← links)
• Neuropharmacology of the Neuropsychiatric Symptoms of Dementia and Role of Pain: Essential Oil of Bergamot as a Novel Therapeutic Approach (Q91715548) (← links)